At a glance
ClinicalIndex Comparison Record- ✓Age 18–60 years
- ✓Confirmed HIV infection
- ✓Stable antiretroviral therapy for ≥12 weeks before enrollment
- ✓Waist-to-hip ratio >0.90 (men) or >0.85 (women)
- ✕Use of Megace, anti-diabetic agents, GH, anabolic agents, or high-dose glucocorticoids (prednisone >5 mg/day) within 3 months of enrollment
- ✕Diabetes mellitus
- ✕Other severe chronic illness
- ✕Carpal tunnel syndrome
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Physiologic Growth Hormone Effects in HIV Lipodystrophy
In Brief
A clinical study evaluating recombinant human growth hormone and placebo for AIDS and HIV Infections. Completed, enrolled 56 participants across 1 site.
Detailed Summary
This study will investigate long-term, low-dose growth hormone administration in HIV-infected patients with reduced growth hormone (GH) secretion and increased visceral adiposity. We hypothesize that low-dose growth hormone will reduce visceral fat. Secondary endpoints will include measures of insulin-like growth factor-1 (IGF-1), glucose homeostasis, lipids, blood pressure,bone density, cardiovascular risk and safety parameters.
Study Details
Timeline
Interventions
growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months
placebo subcutaneously once a day, 18 months